SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 272 participants.

Also called NCT02959606

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 272 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02959606
Other papers using this trial's data
  • A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention Scientific reports, 2023-02-13 DOI, PubMed 36781928, PMC9925771 PubMed links an erratum for this paper. Erratum: PMID 39107345 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02959606. Randomized; no masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2019-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study
Condition
Peripheral Arterial Disease
Intervention (Drug)
Sarpogrelate SR 300mg
Intervention (Drug)
Clopidogrel
Lead sponsor
Seoul National University Hospital (class: other)

Record details

Record id
cardio:ct-nct02959606
Content hash
7c0ed9d31545ecf7ca25e2675458dc240e1703242b999cdf187cd54952c396dc